Alvesco, Omnaris and Zetonna (Asthma Medication) is Buildings and Property in United Kingdom that focus on inhalation aerosol business. Founded in 2008. They cover business area such as a portfolio, U.S., product, asthma, allergic rhinitis, ALVESCO, inhalation aerosol, OMNARIS, nasal spray, ZETONNA.
2008
( 16 years old in 2024 )
Inhalation Aerosol
-
Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
England, United Kingdom
Private
a portfolioU.S.productasthmaallergic rhinitisALVESCOinhalation aerosolOMNARISnasal sprayZETONNA
* We use standard office opening hours in near Alvesco, Omnaris and Zetonna (Asthma Medication)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Alvesco, Omnaris And Zetonna (Asthma Medication) is Buildings and Property business from United Kingdom that founded in 2008 (16 years old in 2024), Alvesco, Omnaris and Zetonna (Asthma Medication) business is focusing on Inhalation Aerosol.
Alvesco, Omnaris and Zetonna (Asthma Medication) headquarter office and corporate office address is located in Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA England, United Kingdom.
Alvesco, Omnaris and Zetonna (Asthma Medication) was founded in United Kingdom.
In 2024, Alvesco, Omnaris and Zetonna (Asthma Medication) is currently focus on inhalation aerosol sector.
Above is snippet of Google Trends for "inhalation aerosol" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Alvesco, Omnaris and Zetonna (Asthma Medication), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
